Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genertec Universal Medical Group Co's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was €160 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €374 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Genertec Universal Medical Group Co's annualizedROC % for the quarter that ended in Dec. 2025 was 3.06%.
Genertec Universal Medical Group Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 7.47%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Genertec Universal Medical Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 4.69%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genertec Universal Medical Group Co EBIT Related Terms
Genertec Universal Medical Group Co EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Credit Services subindustry, Genertec Universal Medical Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genertec Universal Medical Group Co EV-to-EBIT vs Credit Services Industry
For the Credit Services industry and Financial Services sector, Genertec Universal Medical Group Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Genertec Universal Medical Group Co's EV-to-EBIT falls into.
Genertec Universal Medical Group Co EBIT Calculation
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €374 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genertec Universal Medical Group Co (FRA:5UM) has a EBIT of €374 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Genertec Universal Medical Group Co.
Is Genertec Universal Medical Group Co's EBIT too high?
Genertec Universal Medical Group Co's current EBIT is €374 Mil. Overall, Genertec Universal Medical Group Co has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genertec Universal Medical Group Co's EBIT compare to V and MA?
Genertec Universal Medical Group Co's EBIT of €374 Mil can be compared against companies in the Credit Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Credit Services company?
A good EBIT depends on the Credit Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Genertec Universal Medical Group Co. Genertec Universal Medical Group Co's current EBIT is €374 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genertec Universal Medical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Genertec Universal Medical Group Co (FRA:5UM) is currently considered Fairly Valued. The stock's GF Value™ is €0.48, compared to a current price of €0.48 — trading 0.4% above its estimated fair value. The current EBIT is €374 Mil. Genertec Universal Medical Group Co's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Genertec Universal Medical Group Co (FRA:5UM), the current EBIT is €374 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genertec Universal Medical Group Co (FRA:5UM) Overvalued in 2026?
Based on GuruFocus' analysis, Genertec Universal Medical Group Co stock appears to be overvalued.
The current stock price of €0.48 is trading 0.4% above its estimated GF Value™ of €0.48.
GuruFocus considers Genertec Universal Medical Group Co to be Fairly Valued.
Key valuation signals for FRA:5UM:
EBIT: €374 Mil
GF Value™: €0.48 vs. price of €0.48 (0.4% above fair value)
No single metric tells the full story. See the FRA:5UM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genertec Universal Medical Group Co Ltd is principally engaged in providing financing to its customers under finance lease arrangements, the provision of advisory services, the sale of medical equipment as well as leases under operating lease arrangements, and the provision of other services. The group has two business segments namely The finance business comprises direct finance leasing, sale-and-leaseback, factoring, operating leases, and advisory services; and Healthcare business comprises includes hospital group business, healthcare technology business and specialty business. Geographically, it derives a majority of its revenue from Mainland China.
48GF Score
Get the complete analysis for FRA:5UM
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5UM has been successfully added to your 
